Formosa Laboratories, Inc. (Taiwan, China)

1. Established in Dec. 1995, Formosa Laboratories, Inc. was firstly engaged in API) wholesale and manufacturing. In Jul. 2008, it was merged with Lianqiao Bio-tech. (Holdings) Company. Formosa Laboratories, Inc. was emerged. 2. After the merger, Formosa Laboratories, Inc. added the R&D and manufacturing of UV filters in addition to original API business. The products are mostly sold to Europe and America. In 2008, the global market share of API is about 1% while the market share of API in Taiwan is about 4.46%. 3. business class and background: A. Chairman Cheng Zheng Yu, P.H.D in medicine and chairman of Lianqiao. B. The major shareholders are Taiwan Yongguang Chemistry Industry, Chairman and his spouse. 4. In Jun. 2009, there are 242 persons. It signed an exclusive contract of UV with Roche in 2002. Affected by the competition between China and India, Roche sold the patent of UV to DSM. Therefore, Formosa Laboratories, Inc. is now the sole supplier. DSM’s market share is about 50%. The major suppliers of chemistries are Pictet, Cosmos, ATUL and FUSO. 5 Technology and Development: A. The technology comes from the self-research and development. Up to now, over 40 kinds of products have been developed. The core technological platform is the continuous gas phase, high-pressure hydrogenation, metal and optical response of organic water. B. API production: Domestic API has been abandoned to avoid price competition. 6. It applied for public offering in Aug. 2009.